Overcoming Compounding's Dark Side July 21 2012| Filed

New Post Public Reply Private Reply Replies (0) Message Board
NITE

Overcoming Compounding's Dark Side
July 21 2012| Filed Under » Financial Theory, Interest Rates, Investing Basics, Portfolio Management, Stocks
Contrary to what we are led to believe, investors can only spend compound returns, not average returns. Nevertheless, the average returns are so often mentioned by those seeking to promote an investment approach. This practice can often mislead investors who don't understand how money is made and lost over a period of time, due to compounding, in markets that move up in one year and down in the next.

SEE: Accelerating Returns With Continuous Compounding

There are two factors that can have a significant impact on the realized returns experienced by investors: the dispersion of returns and the impact of negative returns. Read on to discover the impact these factors could have on your portfolio, and how you can use this knowledge to gain higher compound returns and avoid the negative side of compounding.

Back to Basics
First, let's review the mathematics used to calculate simple and compound averages. The simple return is the mathematical average of a set of numbers. The compound return is a geometric mean, or the single percentage, usually annual, that provides the cumulative effect of a series of returns. The compound return is the mathematical calculation describing the ability of an asset to generate earnings (or losses) that are then reinvested and generate their own earnings (or losses).
Let's say you invested $1,000 in the Dow Jones Industrial Average (DJIA ) in 1900. The average annual return between 1900 and 2005 for the DJIA is 7.3%. Using the annual average of 7.3%, an investor has the illusion that $1,000 invested in 1900 would become $1,752,147 at the end of 2005 because $1,000 compounded annually at 7.3% yields $1,752,147 by the end of 2005.

However, the DJIA was 66.08 at the beginning of 1900 and it ended at 10717.50 in 2005. This results in a compound average of 4.92%. In the market, you only receive compound returns, so $1,000 invested at the beginning of 1900 in the DJIA would result in only $162,547 by the end of 2005. (To keep things simple and relevant to the discussion, dividends, transaction costs and taxes have been excluded.)

What happened? There are two factors that contribute to the lower results from compounding: dispersion of returns around the average and the impact of negative numbers on compounding.

SEE: Using Historical Volatility To Gauge Future Risk

Dispersion of Returns
As the returns in a series of numbers become more dispersed from the average, the compound return declines. The greater the volatility of returns, the greater the drop in the compound return. Some examples will help to demonstrate this. Figure 1 shows five examples of how the dispersion of returns impacts the compound rate.

The first three examples show positive or, at worst, 0% annual returns. Notice how in each case, while the simple average is 10%, the compound average declines as the dispersion of returns widens. However, half the time the stock market moves up or down by 16% or more in a year. In the last two examples, there were losses in one of the years. Note that as the dispersion in returns grows wider, the compound return gets smaller, while the simple average remains the same.

Figure 1

This wide dispersion of returns is a significant contributor to the lower compound returns investors actually receive.

Impact of Negative Returns
It is obvious that negative returns hurt the actual returns realized by investors. Negative returns also significantly impact the positive impact compounding can have on your total return. Again, some examples will demonstrate this problem.
Looking for penny stocks that skyrocket?
In each of the examples in Figure 2, a loss is experienced in one year and the compound average return for the two years is negative. Of particular importance is the percent return required to break even after the loss. As the loss increases, the return required to break even grows significantly as a result of the negative effect of compounding.

Figure 2

Another way to think about the impact of negative returns on compounding is to answer this question, "What if you invested $1,000 and in the first year you earned 20%, and then lost 20% the following year?" If this up and down cycle continued for 20 years, it would create a situation that is not that different from what occurs in the market. How much would you have at the end of 20 years? The answer is a disappointing $664.83 - not exactly something to brag about next time you're at a party.

The impact of dispersion of returns and negative numbers can be deadly to your portfolio. So, how can an investor overcome the dark side of compounding and achieve superior results? Fortunately, there are techniques to make these negative factors work for you.

SEE: How To Calculate Your Investment Return

Overcoming the Dark Side of Compounding
Successful investors know that they must harness the positive power of compounding while overcoming its dark side. Like so many other strategies, this requires a disciplined approach and homework on the part of the investor.

As academic and empirical research has shown, some of a stock's price movements are due to the general trend of the market. When you are on the right side of the trend, compounding works for you, both in up markets as well as down markets. Therefore, the first step is to determine whether the market is in a secular (long-term or multi-year) bull or bear trend. Then invest with the trend. This also holds true for shorter term trends that take place within the secular trends.

SEE: The Utility Of Trendlines

During bull markets it is fairly easy to do well - the common quip is correct, "a rising tide floats all boats." However, during a bear or flat market, different stocks will perform well at different times. In these environments, winning investors seek stocks that offer the best absolute returns in strong sectors. Investors must become good stock pickers rather than just investing in a diversified portfolio of stocks. In such cases, using the value approach to investing can have excellent results. It can also be useful to learn to short the market when the trend is down. Another strategy is to use bonds to build a ladder that provides a relatively safe return that can be used in a weak stock market environment.
During weak markets, when negative compounding can substantially harm your portfolio, it is even more important to employ proven capital management techniques. This starts with trailing stops to minimize losses and/or capture some profit from an investment. Another important technique is to rebalance your portfolio more frequently. Rebalancing capitalizes on short-term cycles in the financial markets. By selling part or all of the top performers in one asset class or sector, it provides capital to invest in new promising opportunities. A variation of this strategy is to sell part of your position when you have a quick gain to capture some profit and move the stop to or above your entry price. In every case, the investor is actively seeking to offset the negative side of compounding or even work with it.

The Bottom Line
Overcoming the dark side of compounding requires that an investor be an active manager of his or her portfolio. This requires learning the skills needed to recognize market trends, find appropriate investment opportunities and then employ proven capital management techniques. Overcoming the negative side of compounding and beating the market can a very satisfying experience, after all, it's your money that's at stake.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Investors Face Pressure Ahead of December 15

Updated Category News Views 3

Investors Eye December 15 Deadline Nothing like a looming deadline to stir up some anxiety among investors, and that's exactly what's going down at D-Wave Quantum Inc. right now. We're talking about the class action lawsuit spearheaded by the firm Robbins Geller Rudman & Dowd LLP. They've sent out a call to arms for investors who suffered significant losses from February...

Continue Reading
Qingdao's Food Trade Triumph at SIAL Paris Booms

Updated Category News Views 3

Qingdao Impresses in the Global Food Arena Well, 2026 is serving up something special from Qingdao. During SIAL Paris, everyone's talking about how Qingdao’s food companies smashed expectations with 82 million yuan in intended orders. You’ve got CCPIT Qingdao pulling the strings, setting up an exhibition platform that was nothing short of top-tier. Staging a Show at...

Continue Reading
Electrolux Trends: Q3 '26 Shows Resilience Amid Challenges

Updated Category News Views 3

Electrolux's Strategic Moves In A Tough Market Electrolux's Q3 2026 paints a gritty picture—yet there's a pulse of resilience underneath the numbers. Net sales bumped up to SEK 33,919m due to a 3.5% organic growth, showing the company's ability to swim through choppy waters. But let's not brush aside the sharp rocks they’re dodging: soaring raw materials and logistics...

Continue Reading
TORL Bio's Ixo-V Drug Shows Promise in Combatting GCT

Updated Category News Views 2

A Beacon of Hope in Germ Cell Tumor Treatment There's something brewing in the oncology world that's worth a nod. TORL BioTherapeutics has rolled out some interesting preliminary data for their hopeful cancer buster, ixotatug vedotin, or Ixo-V. This study is part of a wider effort to take a swing at recurrent germ cell tumors (GCTs) with some tough results already making...

Continue Reading
Innventure Faces Chaotic Legal Storm Over DarkNX Scandal

Updated Category News Views 1

Innventure's DarkNX Project: From Boon to Bane The stock market is no stranger to seismic shifts, but Innventure, Inc.'s recent plunge is a testament to the catastrophic impact missteps can unleash. This whole DarkNX debacle feels more like a meticulous car wreck than a business evolution. Unpacking the Allegations Sitting comfortably under the NASDAQ:INV ticker,...

Continue Reading
Lowcountry Kids to Get Free Helmets at Safety Events

Updated Category News Views 1

Helmets for Kids Initiative Gets Rolling Now, here's a story that's more about community care than cash flow, but hey, sometimes even a grizzled trader like me can nod in appreciation. Christmas Injury Lawyers are putting their money where their mouth is, with the Helmets for Kids initiative staged at two key events in the Lowcountry area. Yep, that's right—the legal...

Continue Reading
ImmunoForge Sets Sights on BIO-Europe 2026 for New Deals

Updated Category News Views 3

Making Waves with Cutting-Edge Drug Platforms Ah, how time flies in the biotech universe. Here we are, with ImmunoForge prepping to flaunt its high-tech gear at the big show in Cologne: BIO-Europe 2026. The company's aiming to gauge attention with its flashy ELP and LMT platforms, primed and ready for strategic partnerships. ELP: Revolutionizing Drug Delivery You've got...

Continue Reading
Greenberg Traurig Eyes Accolades in Middle East Awards

Updated Category News Views 3

Greenberg Traurig Aims for Middle Eastern Legal Dominance Ah, the legal world, where firms jostle like bulls in a market for the prestige of an award—it's not just about the courtroom victories, but also about snatching the right titles at glossy ceremonies. On the docket this time: Greenberg Traurig has its sights set on several prime accolades at the Law Middle East...

Continue Reading
California Contractors Honored for Safety Commitment

Updated Category News Views 9

Commitment to Safety in the Construction Industry When it comes to construction, safety isn’t an afterthought—it’s woven into the very fabric of every project. The 39th Annual Construction Safety Excellence Awards by the Associated General Contractors of California (AGC of California) pits a spotlight on those embodying this ethos. Industry Leaders in Safety Held on...

Continue Reading
Dimethylaminopropylamine Market Eyes $732M by 2035

Updated Category News Views 0

Surfactants and Epoxy Fuel Dimethylaminopropylamine Demand Hot off the presses, folks! Dimethylaminopropylamine, or DMAPA if you're into acronyms, is gearing up for a steady climb to a $731.9 million market value by the year 2035. That's quite the leap from the $452.6 million we saw back in 2025. According to Credence Research's latest estimates, this amine is hitching...

Continue Reading

Top 5 Most Recently Viewed Articles

Bradley J. Ehrman's Strategic Purchase of Dorchester Minerals Shares

Updated Category News Views 109

Bradley J. Ehrman Demonstrates Confidence in Dorchester Minerals Recently, the financial landscape witnessed an intriguing move as Bradley J. Ehrman, the Chief Executive Officer of Dorchester Minerals (NASDAQ: DMLP), opted to invest a substantial $100,008 in company shares. This significant insider purchase, reported through recent SEC filings, underscores his confidence...

Continue Reading
Datasea Anticipates $90 Million Revenue Growth in Fiscal 2025

Updated Category News Views 92

Datasea Projects Significant Revenue Increase for Fiscal 2025 Datasea Inc. (NASDAQ: DTSS) has announced its expectations for a remarkable revenue surge, projecting around $90 million for the fiscal year ending in June 2025. This anticipated figure represents a significant year-over-year increase of 275%, a leap from the previous year's revenue of $24 million. Strong...

Continue Reading
Univera Unveils Innovative RegeniCARE Gift Set for Wellness

Updated Category News Views 233

Univera Launches the RegeniCARE Gift Set for Convenient Wellness Univera has officially released its first RegeniCARE Gift Set, a unique offering designed to enhance joint care and overall wellness. This set is perfect for those seeking an effective and portable health solution. A Comprehensive Solution for Joint Care The RegeniCARE Gift Set includes a premium canister of...

Continue Reading
Apple's Tim Cook Strengthens Ties with China's IT Sector

Updated Category News Views 176

Tim Cook's Commitment to China's Tech Future Tim Cook, the CEO of Apple Inc. (NASDAQ: AAPL), has recently emphasized the importance of the Chinese market through his meetings with key government officials. His latest engagement was with Jin Zhuanglong, the Minister for Industry and Information Technology. This meeting reflects Apple's ongoing strategy to enhance its user...

Continue Reading
Clearmind Medicine Expands Clinical Trials with Key Partnership

Updated Category News Views 121

Clearmind Medicine Expands Clinical Trials with Key Partnership Clearmind Medicine Inc. (NASDAQ: CMND), a forward-thinking biotech company, has taken a significant step in its mission to tackle Alcohol Use Disorder (AUD) through the expansion of its clinical trial network. The company has recently partnered with the Tel Aviv Sourasky Medical Center, adding this esteemed...

Continue Reading